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Graphical Abstract 
 
Minor groove binders designed and synthesised at the University of 
Strathclyde (S-MGBs) are trypanocidal and curative in mouse models of 
disease caused by  the animal parasites, Trypanosoma congolense and 
Trypanosoma vivax. 
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Abstract: Animal African trypanosomiasis (or nagana) is a wasting livestock disease 
found in sub-Saharan Africa and caused by protozoan parasites Trypanosoma 
congolense, T. vivax and T. brucei. Chemotherapy (diamidine diminazene aceturate) 
and chemoprophylaxis (phenanthridine isometamidium) are essential for disease 
control. Current treatments have reduced efficacy due to increased drug 
resistance, the need for new veterinary trypanocides becomes a high-priority. All 
three of the above African species are susceptible to minor groove binding drugs 
from Strathclyde (S-MGBs) which is important because compounds useful in the 
field must have activity across the range of infectious species so that 
characterisation of the infection is not required at diagnosis. Over 100 S-MGBs 
have been evaluated in Glasgow and Switzerland, and compounds with 
development potential have been identified. As an example, S-MGB 234 has been 
shown to be curative in in vivo models of trypanosome infection in mice. 
Importantly S-MGB 234 does not show cross resistance with other 
antitrypanosomal drugs such as diminazine, isometamidium, or ethidium bromide, 
which is consistent with a different route into the parasite’s cell. S-MGBs that 
contain alkene links, such as in S-MGB 234, are the most active sub-class of S-MGB 
and point the way towards structural optimisation.  
Keywords: antitrypanosomal compounds; DNA minor groove binders; cross 
resistance. 
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Introduction 
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From the early stages of our MGB programme we have had evidence for activity against 
kinetoplastid parasites, especially Trypanosoma brucei. Over the last five years the study 
has been developed in collaboration with the University of Glasgow and the Swiss Tropical 
Health Institute, Basel, to reach the stage at which advanced leads and potential 
development candidates have emerged. In reaching this point, some generalities 
concerning structure-activity relationships have been observed. This paper summarises the 
salient features by selecting specific small groups of closely related compounds. 
 
An effective anti-trypanosomal compound for use against African Animal Trypanosomiasis 
(AAT) must be active against all of the species causing disease so that identification of a 
species is not a necessary part of diagnosis. Moreover such a compound must also be 
effective against strains of trypanosomes resistant to currently used drugs such as 
isometamidium and diminazine. Evidence is presented to show that S-MGBs do not show 
cross resistance. 
 
Lastly, a development candidate must be active in an in vivo model of disease. Data 
showing that S-MGBs are curative in a mouse model of trypanosomiasis are presented. 
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Part of the S-MGB library  (about 100 compounds) was screened in vitro against T. congolense 
(IL3000 BF) and ex-vivo against T. vivax (STIB 719/ILRAD 560 BF) for trypanocidal activity. To 
evaluate selectivity against mammalian cells, the toxicity of each compound to the L6 murine cell 
line was determined. 
The S-MGB library consists of compounds of general structure illustrated by S-MGB 234, shown on 
the next slide. Three different N-terminal (head groups) are included, amide, amidine, and alkene, 
of which the alkene in general shows the best anti-infective activity. Examples of differences cause 
by these structural changes are shown in the following slides. 
Five S-MGBs had IC50 less than 100 nM against T. congolense and 7 had IC50  less than 100 nM 
against T. vivax. There was a broad but not exact correlation between the two activities (see 
following slides). On the basis of their determined activities and selectivity indices, 7 S-MGBs were 
chosen for further evaluation of which 3, S-MGBs 234, 235, and 248 were progressed to the in 
vivo disease model stage. 
The data are summarised on the following chart, which shows the activity against T. congolense in 
comparison with that against T. vivax. The bubble size represents the effect on L6 cells; the larger 
the bubble, the lower the toxicity. Perhaps unsurprisingly some of the most active compounds 
(lower left quadrant) are also the most toxic. However, as the data presented in the following 
slides show, several S-MGBs have sufficiently large selectivity indices to warrant further 
investigation. 
Results and discussion 
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Structural features of S-MGBs 
Strathclyde MGBs (S-MGBs) of all three structural types have been investigated. Tertiary amine and amidine tail 
groups have been included. The following chart shows the activity for the S-MGBs against Trypanosoma 
congolense  and T. vivax;  the bubbles represent the toxicity against the L6 cell line, the larger the bubble, the 
lower the toxicity. Significant compounds in this study have been numbered. 
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234 
Tc 0.1 mM SI > 320 
Tv 0.33 mM  SI > 97 
1 
Tc 0.94 mM SI 1.8 
2 
Tc 0.89 mM SI 3.85 
Tv 0.18 mM SI 19.1 
Essential trends of SAR – 1 
Amidine tail group compounds have low toxicity 
235 
Tc 0.084 mM SI 120 
Tv 0.9 mM  SI 11 
Whilst some activities in the pairs above are very similar, the selectivity indices (SIs) differ greatly. Two 
factors may contribute strongly to this. 1. The morpholino tail groups are weakly basic because of self 
association of the MGB and largely unprotonated at physiological pH leading to highly lipophilic 
compounds. 2. In contrast, the amidine tail groups are essentially permanently protonated giving more 
soluble compounds that could be substrates for specific carrier proteins. 
248 
T. congo 0.018 mM SI 283  
T. vivax  0.147 mM SI 35 
Essential trends of SAR – 2 
Head groups have a great influence on activity 
246 
T. congo 0.94 mM SI 2.6   
247 
T. congo 1.03 mM SI 6.9  
Bicyclic heteroaryl head groups, such as 3-quinolyl in 248, in general have higher activity than 
substituted monocyclic head groups such as 4-dimethylaminophenyl (246) and 3-methoxyphenyl (247). 
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200 inactive 
390 T. congo 0.09 mM SI 634 388 T. congo 2.40 mM SI 36.4 
Essential trends of SAR – 3 
Alkenes are the best head group links for activity 
224 inactive 
For this antitrypanosomal activity, but not others, amidine head groups are inactive. Amide head groups 
give activity as good as some alkenes but the one-to-one comparisons, as here, always substantially 
favour the alkene. The importance of the amidine is also evident from the large SI of 390. 
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Comments on SAR 
The trends observed in the previous 3 slides are representative of observations from the full 
collection of S-MGBs studied. Different structural features turn out to contribute to the best 
profiles discovered so far for several different applications of S-MGBs (antibacterial, 
antifungal and antiparasitic). The currently available generalisations are described in the 
accompanying paper ‘Selectivity in anti-infective minor groove binders’. 
 
With respect to this representative set of compounds and the antitrypanosomal activity, 
there is no evident correlation between the activity and typical medicinal chemical 
parameters such as clogP and tPSA. Indeed S-MGBs are characterised by large polar surface 
areas (110 – 150 for the most active alkene-containing compounds) and S-MGBs with clogP 
values in the range 2.5 to 5.0 have all been found to be active. An added complication is the 
known tendency of S-MGBs to aggregate in solution which makes an SAR basis in 
physicochemical properties difficult to define (see Parkinson et al., Med. Chem. Commun., 
2013, 4, 1105-1108). 
 
The range of activities observed might be understood through different DNA-binding 
properties and by different uptake / efflux into and from target cells. Because of the 
multiple local targets expected on trypanosomal DNA there are no data with which to 
discriminate between compounds for DNA binding. The following biological evaluation, 
however, implicates uptake as important in the activity of S-MGBs. 
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S-MGB 
T. congolense WT 
EC50 (µM) 
T. congolense 
DimR EC50 (µM) 
RF 
T. congolense 
EMS MUT DimR 
EC50 (µM) 
RF 
248 0.27 ± 0.02 0.18 ± 0.01 0.7 0.22 ± 0.03 0.8 
234 0.51 ± 0.06 0.64 ± 0.03 1.3 0.70 ± 0.005 1.4 
235 1.40 ± 0.24 0.66 ± 0.08 0.5 1.19 ± 0.12 0.9 
246 2.13 ± 0.17 1.82 ± 0.06 0.9 2.03 ± 0.07 1.0 
247 2.36 ± 0.10 1.66 ± 0.10 0.7 1.78 ± 0.10 0.8 
2 4.50 ± 0.22 4.41 ± 0.25 1.0 4.52 ± 0.18 1.0 
1 7.99 ± 0.85 5.26 ± 0.15 0.7 6.68 ± 1.06 0.8 
Diminazene 0.20 ± 0.01 2.06 ± 0.10 10.4 2.36 ± 0.10 12.0 
 
In vitro trypanocidal activity of selected S-MGBs against two diminazene-resistant T. congolense lines 
(DimR and EMS MUT DimR) as compared to wild type (WT) (mean ± SEM, n≥3) were determined at the 
University of Glasgow. Ratios (RF) close to unity indicate that the two strains compared are of 
essentially equal sensitivity to the S-MGB. The data suggest that the S-MGBs do not act by the same 
mechanism as diminazene; both differences in uptake and differences in intracellular activity may 
contribute. 
(Note: The EC50 data here differ from those reported in the SAR comparisons because the latter were 
obtained at the Swiss Tropical Health Institute under slightly different conditions.) 
Evidence for lack of cross resistance to diminazene 
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S-MGB 234 and 235 have significant in vivo activity against T. congolense STIB 736/IL1180 
mouse model of infection. The positive curative effects and the significant length of survival (at 
least to end of experiment) are notable. In view of this and the lack of cross resistance, 
understanding the mechanism of action of S-MGBs becomes important. Some relevant 
information is presented in the following slides. 
MRD = mean day of relapse. MSD = mean days of survival 
In vivo activity against T. congolense  
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Conventional diamidine minor groove binding trypanocidal drugs cause destruction of the 
kinetoplast, which is an essential component of their mechanism of action. S-MGBs might be 
expected to show similar effects. This has been tested using ISMR1, which is a T. b. brucei  in vitro-
generated isometamidium resistant line with reduced mitochondrial membrane potential and loss 
of kinetoplast. 
  
Evidence for significance of kinetoplast in S-MGB activity 
S-MGB 234 is as active against akinetoplastic T. b. brucei , ISMR1, as it is against wild type.  This 
strain is resistant to diminazene and to the phenanthridines, isometamidium and ethidium 
bromide. 
The presence of the kinetoplast therefore is not necessary for the trypanocidal activity of the 
S-MGBs. This is a distinctive feature of their mechanism of action. 
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Although S-MGB 234 does not cause destruction of the kinetoplast it has major effects on the DNA-containing 
organelles. Treatment of T. b. brucei with S-MGB 234 causes aberrations in the DNA-containing organelles, their 
segregation and their morphology as well as an apparent block of cytokinesis. An accumulation of cells with 
multiple kinetoplasts and nuclei (MKMN) is observed over time in the treated parasite population.  
Exposure to S-MGB 234 (5 × EC50) for 10 h has irreversible effects on T. congolense survival showing that this S-
MGB, and presumably others, is cytocidal. 
The effect of S-MGB 234 on kinetoplast and nucleus 
16 
0
20
40
60
80
100
120
140
160
180
0 20 40 60
V
ia
b
il
it
y
 (
%
  
to
 c
o
n
tr
o
l)
 
  
Time (hours)  
T. b. brucei Lister 427 BF  
0
20
40
60
80
100
120
140
160
180
0 20 40 60 80
Time (hours)  
T. congolense IL3000 BF  
EC50
5xEC50
10xEC50
S-MGBs do not act fast. Exposure to 5×EC50 S-MGB 234 kills most T. b. brucei within 48 h and 
sterilises T. congolense cultures within 72 h. Abnormal, sick cells are visible before death occurs. 
Treated cells do not proliferate, which is further evidence for cytocidal activity. 
Time to kill and cytocidal activity 
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Antitrypanosomal activity compared with antibacterial 
Evidence has been obtained from metabolomics studies which show that many metabolite levels 
are altered on treatment of T. b. brucei with S-MGB 234 (5 × EC50, 8 h). The major changes in 
identified metabolites were in the nucleoside / nucleotide pool together with some derived 
cofactors (pyridoxine and pyridoxamine). 2-Oxoglutarate was also found to have a significant 
change. These changes relate to two of those observed in the bacterial experiments using RNA-
seq methodology. 
 
The metabolomics observations can be compared with the results from RNA-seq experiments 
using another S-MGB (3) attacking Staphylococcus aureus (see paper ‘Why antibacterial minor 
groove binders are a good thing.). In the latter case, challenge with S-MGB-3 caused hundreds of 
changes in gene expression, up and down regulation, that could be mapped on to several areas of 
metabolism. One of the most prominent of these was nucleotide metabolism. Energy production 
and lipid metabolism were also affected. There are thus some similarities between the effects of 
the S-MGBs on the two very different species. 
 
It can be suggested, therefore, that S-MGB 234 by binding to trypanosomal DNA causes multiple 
biological effects in a manner related to that by which S-MGB 3 affects S. aureus.  Since the 
selectivity of S-MGB 234 appears to be due to an uptake mechanism different from that of current 
drugs, a change in transporter availability or effectiveness may lead to resistance. 
 
Conclusions 
18 
S-MGBs as a class have significant antitrypanosomal activity that shows clear structure-activity 
patterns. 
• Amidine tail groups provide the best balance between activity and  in vitro toxicity. 
• Weakly basic tail groups are associated with compounds with higher toxicity. 
• The most active compounds have arylalkenyl head groups and amidine tail groups. 
S-MGBs are promising leads for the treatment  of animal African trypanosomiasis. 
•  Good in vitro activity combines with proved in vivo efficacy against relevant Trypanosoma 
species; 
•  They are active in vitro against parasites resistant to currently used veterinary trypanocides. 
Despite being both minor groove binders, S-MGBs and diamidines are unlikely to be cross-
resistant. 
• S-MGBs do not share the same transporters involved in diamidine uptake and resistance in T. b. 
brucei. 
• The kinetoplast, which is disintegrated by diamidine exposure, is not the main target of the S-
MGBs. 
S-MGBs are cytocidal and affect cell division. 
•  Treated parasites do not proliferate and are unable to undergo correct cytokinesis. 
•  Some nucleotides accumulate in treated parasites, possibly due to decrease in DNA synthesis or 
to DNA disintegration. 
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